A5101734182- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- Heavy metals in environment
- Immunotherapy and Immune Responses
- Cancer Research and Treatments
- Geochemistry and Elemental Analysis
- Environmental Toxicology and Ecotoxicology
- Neural and Behavioral Psychology Studies
- Acupuncture Treatment Research Studies
- Adsorption and biosorption for pollutant removal
- Transcranial Magnetic Stimulation Studies
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Melanoma and MAPK Pathways
- Water Quality and Pollution Assessment
- Advanced Numerical Analysis Techniques
- Algal biology and biofuel production
- Neuroinflammation and Neurodegeneration Mechanisms
- Fibroblast Growth Factor Research
- Photochromic and Fluorescence Chemistry
- Lung Cancer Treatments and Mutations
- Galectins and Cancer Biology
- Photoreceptor and optogenetics research
- Simulation and Modeling Applications
- Electrochemical Analysis and Applications
- Numerical Methods and Algorithms
Zhejiang University of Technology
2011-2025
Chengdu University of Traditional Chinese Medicine
2024-2025
Shanghai Industrial Technology Institute
2025
Peking University
2012-2025
National Clinical Research Center for Digestive Diseases
2025
Theravance Biopharma (United States)
2020-2024
ZheJiang Academy of Agricultural Sciences
2023
China Pharmaceutical University
2020-2023
Nanjing University of Chinese Medicine
2017-2022
FibroGen (United States)
2016-2020
Effective treatment options are limited for patients with advanced (metastatic or unresectable) melanoma who progress after immune checkpoint inhibitors and targeted therapies. Adoptive cell therapy using tumor-infiltrating lymphocytes has demonstrated efficacy in melanoma. Lifileucel is an autologous, centrally manufactured lymphocyte product.We conducted a phase II open-label, single-arm, multicenter study had been previously treated inhibitor(s) BRAF ± MEK agents. was produced from...
Patients with advanced melanoma have limited treatment options after progression on immune checkpoint inhibitors (ICI). Lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, demonstrated an investigator-assessed objective response rate (ORR) of 36% in 66 patients who progressed ICI and targeted therapy. Herein, we report independent review committee (IRC)-assessed outcomes 153 treated lifileucel large multicenter Phase 2 therapy trial melanoma.Eligible had that...
Summary Aims Manganese superoxide dismutase ( M n SOD ), one of the most crucial antioxidant enzymes in central nervous system, is thought to be major mechanisms by which cells counteract injuries reactive oxygen species after cerebral ischemia. In this study, we used a novel synthesized compound T m4 P y ) with highly effective activity study therapeutic potential and possible underlying Methods Primary cultured cortical neurons were examine protective effect compounds. Mice middle artery...
10006 Background: Treatment options are limited for patients with advanced melanoma who have progressed on checkpoint inhibitors and targeted therapies. Adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) leverages enhances the body’s natural defense against cancer has shown durable responses in heavily pretreated patients. Methods: C-144-01 is a global Phase 2 open-label, multicenter study of efficacy & safety lifileucel unresectable metastatic BRAF/MEK inhibitors, if BRAF...
Abstract The skin stratum corneum (SC) barrier function will interfere with the absorption of topical treatment and reduce drug's therapeutic effect on alopecia. Microneedles (MNs) can penetrate deliver drugs to dermis. Furthermore, MNs mechanically stimulate skin, which promotes hair growth. Thus, we designed a green dissolvable composite microneedle made hyaluronic acid (HA) Bletilla striata polysaccharide (BSP) encapsulate cholesterol-free ginsenoside Rg3 liposomes (Rg3-LPs) avoid...
// Yuping Tang 1, 2, * , Guisheng Zhou Lijun Yao 3 Ping Xue 4 Danhong Yu 5 Renjie Xu 6 Wen Shi 2 Xin Zhaowei Yan and Jin-Ao Duan 1 Shaanxi Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, University Medicine, Xianyang, 712083, China Jiangsu Nanjing Nanjing, 210023, Department Pharmacy, The First Affiliated Hospital Soochow University, Suzhou, 215006, Changzhou Institute for Food Drug Control, Changzhou, 213000, Children’s to Shaoxing Second Hospital,...
The large proportion of patients (pts) with advanced (unresectable or metastatic) melanoma resistant to immune checkpoint inhibitors (ICI) define a significant unmet need. Lifileucel, one-time autologous TIL cell therapy, has demonstrated durable clinical benefit in this setting, the C-144-01 study showing an ORR 31.4% heavily pre-treated population. We report 4-year follow-up data from on lifileucel's treatment outcomes and patterns response. (NCT02360579) is prospective, open-label,...
Microfluidic-engineered hydrogel microspheres have emerged as a promising avenue for advancements in tissue engineering and regenerative medicine, particularly through the precise manipulation of fluids to achieve personalized composite biomaterials. In this study, we employed microfluidic technology fabricate (HMs) using Chinese herbal Bletilla striata polysaccharide (BSP) primary material. Concurrently, natural active ingredient 20(S)-protopanaxadiol (PPD) was encapsulated within HMs form...
9505 Background: Immune checkpoint inhibitors (ICI) have become standard of care for treatment metastatic melanoma. Most patients with advanced melanoma progress on ICI and options are limited these patients. Progression may be through primary resistance (lack response) or secondary (initial response then progression). Lifileucel is an adoptive cell therapy using TIL, that has shown efficacy in who on/after anti-PD-1 (Sarnaik, 2020). We present the 28-month (mos) follow-up data highlight...
<h3>Background</h3> Immune checkpoint inhibitors (ICI) are standard-of-care in the treatment of several types cancer; however, an unmet medical need exists for early-line combination therapies that able to provide higher response rates, more durable responses, and manageable long-term safety. Lifileucel (LN-144) LN-145, adoptive cell using tumor-infiltrating lymphocytes (TIL), have demonstrated encouraging efficacy with acceptable safety patients advanced cancer has failed ICI.<sup>1–2</sup>...